Each tablet contains:
Active ingredient:
Chymotrypsin | 4200 USP units |
Excipients: Maltodextrin, aspartame, compri M3 fine, menthol powder, magnesium stearate.
INDICATIONS
BOSTRYPSIN is used for treatment of post - traumatic or postoperation oedema (i.e., soft tissue injuries, acute traumatic injuries, sprains, contusions, hematomas, ecchymoses, infections, edema of the eyelids , muscle cramps, and sports injuries).
ADMINISTRATION AND DOSAGE
Administration
Tablets should also be taken with at least 8 oz (ounce) equivalent to 240 ml of water to help activate the enzyme.
Dosage
2 tablets, 3 to 4 times/day.
CONTRAINDICATIONS
Hypersensitivity to chymotrypsin or any of the other components of the product.
Chymotrypsin is contraindicated in patients with decreased alpha 1 antitrypsine. Generally, patients with COPD, especially emphysema and patients presenting with nephrotic syndrome are also likely candidates for decreased alpha 1 antitrypsine.
WARNINGS AND PRECAUTIONS
Chymotrypsin is generally well tolerated and not associated with any significant side effects.
People who should not use enzyme therapy include those with hereditary clotting disorders such as hemophilia, those suffering from coagulation disturbances, those who are just about to or have undergone surgery, those on anticoagulant therapy, anyone suffering from protein allergies, and pregnant women or those breast-feeding, patient has stomach ulcers.
Important information about excipients
BOSTRYPSIN contains 6 mg aspartame in each tablet. Neither non-clinical nor clinical data are available to assess aspartame use in infants below 12 weeks of age.
PREGNANCY AND LACTATION
Chymotrypsin should not be used in pregnant and breast-feeding women.
SHELF-LIFE
24 months from the manufacturing date. Do not use after the expiry date.